- ProLindac Is Safe And Active in Recurrent Ovarian Cancer; Unique Design Simulates 4-Day Continuous Infusion -
DALLAS, Oct. 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that three posters describing significant recent results of the company's proprietary polymer DACH platinum prodrug, ProLindac, in clinical and preclinical studies are being presented this week at a major international oncology conference held in Geneva, Switzerland.
The clinical poster highlights results from the multi-center Phase 2 recurrent ovarian cancer trial in France where the level of anti-cancer activity of ProLindac in a heavily-pretreated patient population compares favorably to previously published results of single agent oxaliplatin in patients that had less pretreatment. These promising efficacy results were obtained without significant toxicity or other significant side-effects. The two preclinical posters, describing studies performed by Access collaborators at prominent Institutes in France, demonstrate the potential benefits of ProLindac over current platinum therapies: one highlights the observation that ProLindac uses albumin as a carrier, slowing blood clearance, which provides for a sustained tumor exposure to platinum. The other poster highlights that the antiproliferative effects of ProLindac are associated with an increase in expression of p21, a gene associated with cell cycle control.
"The latest results from our clinical study in advanced ovarian cancer
patients continue to demonstrate that ProLindac is active in ovarian cancer
with mild side-effects," stated David P. Nowotnik, Access' Senior Vice
President Research and Development. "The two preclinical posters show that,
mechanistically, ProLindac is similar to the approved DACH platinum
compound, oxaliplatin, while benefiting from Access' proprietary polymer
targeting technology. Our unique design enables targeted delivery of higher
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved